ABBV-400 in Select Advanced Solid Tumor Indications - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if an experimental drug called ABBV-400 (the study drug) is a safe and effective option for treating various types of solid tumors.

What is the Condition Being Studied?

Advanced Solid Tumors

Who Can Participate in the Study?

Adults ages 18+ who are diagnosed with one of the following types of cancer that is advanced or metastatic:

- Hepatocellular carcinoma (HCC); OR

- Biliary tract cancer (BTC); OR

- Pancreatic ductal adenocarcinoma (PDAC); OR

- Esophageal squamous cell carcinoma (ESCC); OR

- Triple-negative breast cancer (TNBC); OR

- HR-positive and HER2-negative breast cancer (HR+/HER-); OR

- Head and neck squamous cell carcinoma (HNSCC)

For more information about who can join this study, please contact the study team at or 919-668-1861.

Age Group

What is Involved?

If you choose to join this study, you will:

- Get the study drug through an IV once every 3 weeks

- Have a tumor biopsy done, if necessary

- Have blood draws

- Have imaging scans (CT or MRI)

Study Details

Full Title
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00113960
NCT: NCT06084481
Phase I
Enrollment Status
Open for Enrollment